Recent developments with macrolide antibiotics

摘要: Macrolide antibiotics have recently experienced a significant renaissance with the introduction of several new semi-synthetic derivatives, and subsequent research has identified many additional opportunities for useful agents. Modifications at position C-3 erythromycin been especially promising, yielding ‘ketolides’ such as HMR 3647, well other investigational compounds from Taisho Abbott. Within 16-membered macrolides, series derivatives leucomycins repromicin disclosed by Meiji Seika Pfizer, respectively. Advances in molecular biology genetics macrolide-producing organisms now made feasible directed biosynthesis hybrid structures methodologies that it is becoming possible to employ on combinatorial scale. Finally, non-anti-infective activities associated macrolides are being pursued, gastrointestinal prokinetic (motilides).